TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06635252
Drug: STA 4783
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
Study: NCT05351086
Drug: PUR3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
Study: NCT05658029
Drug: ARINA-1
Normalized name: ZOSTERA MARINA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
Study: NCT06574269
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
Study: NCT06574269
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC590 Dose 1
Study: NCT06574269
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC590 Dose 2
Study: NCT06574269
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: The MTD of TLC590
Study: NCT06574269
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC590 Dose 3 (The SMC-suggested dose)
Study: NCT06574269
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC590
Study: NCT05844956
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Study: NCT04374903
Drug: HCQ & AZ vs HCQ+SIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
Study: NCT06450028
Drug: 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.
Study: NCT06450028
Drug: 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.
Study: NCT05217732
Drug: ZX-7101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT06076330
Drug: Plasmalyte
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
Study: NCT05217732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05041543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as eye drops
Study: NCT04044534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will receive placebo.
Study: NCT05883852
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
Study: NCT05655182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
Study: NCT04452344
Drug: opioid-containing analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocodone/ acetaminophen combination product
Study: NCT04452344
Drug: two over-the-counter analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of over-the-counter analgesics (ibuprofen/acetaminophen)
Study: NCT05385705
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
Study: NCT06405204
Drug: Myoinositol
Normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an enzymatic isoform of inositol and belongs to the vitamin B complex family
Study: NCT06405204
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
Study: NCT06405204
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control
Study: NCT06675929
Drug: Placebo for BI 770371
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for BI 770371
Study: NCT06615557
Drug: Fasedienol Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray delivered 20 minutes before the PSC
Study: NCT04888221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously (SC) weekly during 24 weeks
Study: NCT06613685
Drug: GS-1720/GS-4182 FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT05341089
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05244525
Drug: Bupivacaine with Epinephrine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
Study: NCT05581693
Drug: L04RD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of L04RD1
Study: NCT05581693
Drug: L04TD2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of L04TD2
Study: NCT03939273
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: seven day course of placebo tablets and capsules identical in appearance and number to active treatment
Study: NCT05368805
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
Study: NCT05582499
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT03771612
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
Study: NCT03771612
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the participants will be randomly assigned to receive a placebo pill twice daily
Study: NCT06680622
Drug: bemarituzumab, trifluridine/tipiracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3 will receive bemarituzumab plus SOC treatment with trifluridine/tipiracil
Study: NCT05857046
Drug: Melatonin 10 MG
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
Study: NCT04692493
Drug: non-TNFi-biologic class
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
Study: NCT04470752
Drug: InOrpha Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycerol based suspension vehicle
Study: NCT06079346
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folinic acid, 5-FU, Irinotecan, Oxaliplatin
Study: NCT04620473
Drug: Capeox
Approvals — FDA: no, EMA: no, PMDA: no
Description: to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
Study: NCT05087940
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
Study: NCT06619236
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05331183
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablets for oral administration.
Study: NCT06663748
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
Study: NCT05323487
Drug: Bumetanide Injection
Normalized name: bumetanide Injection
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
Study: NCT06533384
Drug: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Study: NCT05886192
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norepinephrine
Study: NCT05861947
Drug: AUR106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once or twice daily
Study: NCT05031624
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of normal saline
Study: NCT01549847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO BID
Study: NCT05429684
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
Study: NCT05212532
Drug: EOM613
Approvals — FDA: no, EMA: no, PMDA: no
Description: peptide nucleic acid (PNA)
Study: NCT05020483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
Study: NCT06130384
Drug: Use of bromfenac 0.09% to reduce intravitreal injection pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eyedrop (bromfenac) will be given to the assigned eye.
Study: NCT06130384
Drug: Use of artificial tears to reduce intravitreal injection pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eyedrop (artificial tears) will be given to the assigned eye.
Study: NCT06658899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match CRD-4730 in tablet form
Study: NCT04859803
Drug: conventional intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
Study: NCT05595499
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06001125
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 20 mg PO weekly
Study: NCT05673135
Drug: Anti-Hypertensive
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For control of the blood pressure
Study: NCT05437029
Drug: Q-Griffithsin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
Study: NCT04827537
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (one pill) x two times a day orally, 10 consecutive days
Study: NCT06671444
Drug: YZJ-1139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, 20 mg tablet
Study: NCT06673134
Drug: enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: exclusive enteral nutrition therapy or Partial enteral nutrition
Study: NCT06673134
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc
Study: NCT06672263
Drug: TQB3911 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.
Study: NCT06619990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06377098
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo table given orally every eight hours up to three times while mother is in labor
Study: NCT05441046
Drug: Genakumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: genakumab plus tislelizumab 200 mg
Study: NCT04645797
Drug: APR003
Approvals — FDA: no, EMA: no, PMDA: no
Description: This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
Study: NCT06534697
Drug: Naropin, 0.2% Injectable Solution in dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
Study: NCT06530316
Drug: RET Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: RET inhibitors for neoadjuvant treatment
Study: NCT05634590
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
Study: NCT05634590
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
Study: NCT04770272
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, day 1 for 4 cycles (12 weeks)
Study: NCT04651777
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
Study: NCT04855877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of lactose tablet (placebo)
Study: NCT05914753
Drug: Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
Study: NCT05914753
Drug: Epirubicin, Cyclophosphamide, Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
Study: NCT06172257
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Study: NCT04906005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
Study: NCT02005523
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05457530
Drug: DOR/3TC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
Study: NCT05457530
Drug: BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
Study: NCT06608277
Drug: Group B active comparator
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator: Group B = Sham Stellate Ganglion Block plus ketamine infusion
Study: NCT05386433
Drug: standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-of-care of COVID-19
Study: NCT06512766
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study: NCT06512766
Drug: Retinoids
Normalized name: Retinoids for cancer treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study: NCT06674460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet, to be taken sublingually, twice daily
Study: NCT06243835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo enteric coated tablets identically matched to the Kindolor Tosylate tablets with equal amount of Prosolv SMCC replacing the Kindolor Tosylate
Study: NCT05035316
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
Study: NCT05035316
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet: calcium, 1 tablet/day
Study: NCT06511869
Drug: AZD4205
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
Study: NCT04634539
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
Study: NCT05878938
Drug: NNC0365-3769 (Mim8) PPX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
Study: NCT05379322
Drug: Anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
Study: NCT05379322
Drug: JAK inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
Study: NCT06252610
Drug: Radiotracer Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably.